Statins are the current basis of lipid-lowering therapy, despite which may have 
limitations on efficacy and safety. In high risk patients who do not achieve 
current lipid goals, in those intolerant to statins or those with atherogenic 
dyslipidemia, it is possible combine two or more lipid lowering drugs, including 
statins, ezetimibe, bile acid sequestrants, fibrates, niacin and prescription 
omega-3 fatty acids. However, for most of these combination therapies pivotal 
data on clinical outcomes are still lacking.